<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medicis Pharmaceutical Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/medicis-pharmaceutical-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SLTM) Solta Medical Reports LipoSonix Approval</title>
		<link>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028</link>
		<comments>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:26:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86028</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) reported that Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), has won the U.S. approval for the second-generation LIPOSONIX system for non-invasive waist circumference reduction. Solta announced, in September 2011, the acquisition of Medicis Technologies Corporation in a deal worth $35 million. The acquisition, which is expected to be completed in fourth-quarter 2011, provides Solta with Medicis’ LIPOSONIX system which uses advanced non-invasive ultrasound energy to reduce abdominal fat. Under the agreement, Solta will pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRX) Medicis Pharmaceutical Sells LipoSonix Business</title>
		<link>http://www.stockbloghub.com/2011/09/20/mrx-medicis-pharmaceutical-sells-liposonix-business/83304</link>
		<comments>http://www.stockbloghub.com/2011/09/20/mrx-medicis-pharmaceutical-sells-liposonix-business/83304#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:26:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83304</guid>
		<description><![CDATA[Medicis Pharmaceutical Corp. (MRX) recently announced to have entered into a ‘Stock Purchase Agreement’ with Solta Medical, Inc. (SLTM), under which the latter will acquire all the outstanding shares of Medicis Technologies Corporation (formerly LipoSonix, Inc.), a subsidiary of Medicis Pharma. The deal is expected to close in the fourth quarter of 2011. According to the agreement, Solta will make a payment of $15 million to Medicis Pharma following the closure of the deal. Additionally, Solta will pay up to $20 million to Medicis Pharma on the achievement of certain regulatory milestones. Medicis Pharma is also entitled to receive payments based on the future performance of the LipoSonix technologies. Solta&#8217;s obligation to make these additional future payments expires after about 7 years. We note that the LipoSonix system is currently ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/mrx-medicis-pharmaceutical-sells-liposonix-business/83304/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLTM) Solta Medical Buying Medicis Unit</title>
		<link>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359</link>
		<comments>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:05:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83359</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) has agreed to acquire Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), in a deal worth roughly $35 million. Under the agreement, Soltawill pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial milestones. The acquisition, which is subject to customary closing conditions including antitrust clearance, is expected to close in fourth-quarter 2011. Solta plans to finance the transaction through its existing cash and credit facilities. The acquisition provides Solta with Medicis’ LIPOSONIX system, which uses advanced non-invasive ultrasound energy to reduce abdominal fat. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGII) Company News for August 9, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/09/agii-company-news-for-august-9-2011-corporate-summary/80946</link>
		<comments>http://www.stockbloghub.com/2011/08/09/agii-company-news-for-august-9-2011-corporate-summary/80946#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:08:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[AGII]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[American International Group Inc]]></category>
		<category><![CDATA[Argo Group International Holdings Limited]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Berkshire Hathaway]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[BRKA]]></category>
		<category><![CDATA[BRKB]]></category>
		<category><![CDATA[DG FastChannel Inc]]></category>
		<category><![CDATA[DGIT]]></category>
		<category><![CDATA[Dollar Thrifty Automotive Group Inc]]></category>
		<category><![CDATA[DTG]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JB Hunt Transport Services Inc]]></category>
		<category><![CDATA[JBHT]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Transatlantic Holdings Inc.]]></category>
		<category><![CDATA[TRH]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80946</guid>
		<description><![CDATA[•    Share prices of America&#8217;s biggest bank, Bank of America Corp. (NYSE:BAC) fell 20.32% after a report in the New York Times said that American International Group, Inc. (NYSE:AIG) has filed a suit against the bank to recover more than $10 billion in losses due to mortgage-backed securities •    Car rental company Dollar Thrifty Automotive Group, Inc.&#8217;s (NYSE:DTG) shares declined by 12.75% to close at $58.79 after the company posted second quarter earnings results that came in below expectations •    Share prices of DG FastChannel Inc. (NASDAQ:DGIT) fell 24.95% after the company, which is primarily engaged in advertising and distribution, reported a fall in quarterly revenue results that came in below estimates •    Telecom-software maker BroadSoft Inc.’s  (NASDAQ:BSFT) share prices rose 9.70% after the company&#8217;s forecasted earnings for fiscal 2011 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/agii-company-news-for-august-9-2011-corporate-summary/80946/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats &#8211; Revisits Guidance</title>
		<link>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566</link>
		<comments>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566#comments</comments>
		<pubDate>Wed, 03 Aug 2011 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAP Pharmaceuticals Inc]]></category>
		<category><![CDATA[MAPP]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80566</guid>
		<description><![CDATA[Allergan, Inc.’s (AGN) second quarter 2011 earnings of 96 cents per share inched ahead of the Zacks Consensus Estimate by a penny and surpassed the company’s guidance range of 93 – 95 cents. Earnings increased 12.9% from the year-ago quarter. Revenues Revenues increased 13.6% to $1,417.2 million, easily exceeding the Zacks Consensus Estimate of $1,339 million. Specialty pharmaceuticals sales increased 14.0% to $1,155.3 million, with eye care pharmaceutical sales increasing 13.8%. Strong performance of products like Lumigan and Restasis helped drive eye-care sales. Alphagan and Combigan franchise sales went up 4.1% to $108.5 million in the reported quarter. New product Latisse contributed $21.9 million to the second quarter sales. Botox sales increased 16.1% year on year to $418.4 million. Going forward, Allergan is looking to boost Botox sales by gaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/agn-allergan-beats-revisits-guidance/80566/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BAC) Company News for July 15, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/16/bac-company-news-for-july-15-2011-corporate-summary/79166</link>
		<comments>http://www.stockbloghub.com/2011/07/16/bac-company-news-for-july-15-2011-corporate-summary/79166#comments</comments>
		<pubDate>Sat, 16 Jul 2011 21:31:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Money Center Banks]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[Energy Transfer Equity L.P.]]></category>
		<category><![CDATA[ETE]]></category>
		<category><![CDATA[Fairchild Semiconductor International Inc]]></category>
		<category><![CDATA[FCS]]></category>
		<category><![CDATA[FEIM]]></category>
		<category><![CDATA[Frequency Electronics Inc]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Lloyds Banking Group plc]]></category>
		<category><![CDATA[LYG]]></category>
		<category><![CDATA[MAR]]></category>
		<category><![CDATA[Marriott International Inc.]]></category>
		<category><![CDATA[MBI]]></category>
		<category><![CDATA[MBIA Inc.]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[NTRI]]></category>
		<category><![CDATA[NutriSystem Inc.]]></category>
		<category><![CDATA[RTI]]></category>
		<category><![CDATA[RTI International Metals Inc]]></category>
		<category><![CDATA[Southern Union Company]]></category>
		<category><![CDATA[SUG]]></category>
		<category><![CDATA[Williams Companies Inc.]]></category>
		<category><![CDATA[WMB]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79166</guid>
		<description><![CDATA[•    Share prices of ConocoPhillips (NYSE:COP) increased 1.63% after the board of directors authorized the division of the energy company into two publicly traded firms •    Maker of chips for mobiles, PC&#8217;s and automobiles Fairchild Semiconductor&#8217;s (NYSE:FCS) shares gained 2.85% to close at $16.59 after the company released an optimistic outlook for the fiscal •    Analysts at Wedbush upgraded NutriSystem Inc. (NASDAQ:NTRI) from “Neutral” rating to an “Outperform” rating with a target price of $19 on its stock. Following this upgrade, the shares gained 5.44% to close at $15.11 •    U.S. listed shares of Lloyds Banking Group PLC (NYSE:LYG) gained momentum in the day’s trade after Goldman Sachs (NYSE:GS) added the London bank to its conviction &#8220;Buy&#8221; list citing  the  bank has little exposure in the ongoing European debt crisis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/16/bac-company-news-for-july-15-2011-corporate-summary/79166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AKAM) Stock Market News for February 11, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/02/12/akam-stock-market-news-for-february-11-2011-market-news/66819</link>
		<comments>http://www.stockbloghub.com/2011/02/12/akam-stock-market-news-for-february-11-2011-market-news/66819#comments</comments>
		<pubDate>Sat, 12 Feb 2011 18:43:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Internet Information Providers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AKAM]]></category>
		<category><![CDATA[Akamai Technologies Inc.]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[Clearwire Corporation]]></category>
		<category><![CDATA[CLWR]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66819</guid>
		<description><![CDATA[On Thursday, a late day rally helped the market to close almost flat following Egyptian President Hosni Mubarak’s speech. Though the President said he was not resigning, Mubarak will delegate powers to the Vice President. Earlier in the day markets fell after network equipment maker Cisco (NASDAQ:CSCO) projected a weak outlook. The Dow Jones Industrial Average ended the day lower by 10.60 points to 12,229.29. The S&#38;P 500 gained 0.07% to close at 1,321.87. The Nasdaq rose 1.83 points to end the day at 2,790.45. Market breadth was positive as rising shares slightly outpaced falling ones by a small margin. Overall 4.2 billion shares were traded on a consolidated basis. On the international front, the markets reacted late in the day to Egyptian President Hosni Mubarak’s announcement that he will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/12/akam-stock-market-news-for-february-11-2011-market-news/66819/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Wins FDA Approval For Label Expansion on Botox</title>
		<link>http://www.stockbloghub.com/2010/03/12/agn-allergan-wins-fda-approval-for-label-expansion-on-botox/30504</link>
		<comments>http://www.stockbloghub.com/2010/03/12/agn-allergan-wins-fda-approval-for-label-expansion-on-botox/30504#comments</comments>
		<pubDate>Fri, 12 Mar 2010 18:51:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30504</guid>
		<description><![CDATA[Allergan, Inc. (AGN) recently received good news with the US Food and Drug Administration (FDA) granting approval to Botox for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity. The FDA approval comes after the company submitted additional data following the receipt of a complete response letter from the agency in May 2009. Botox was originally developed for the treatment of certain ophthalmic movement disorders, but has since seen strong growth thanks to approval for additional indications. Although Botox is known more for its cosmetic uses, therapeutic indications accounted for 52% of total Botox sales in 2009. Allergan has been working on gaining approval for additional indications for Botox. Botox sales declined marginally in 2009 mainly due to weak consumer spending, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/12/agn-allergan-wins-fda-approval-for-label-expansion-on-botox/30504/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats The Street &#8211; Outlook Disappoints</title>
		<link>http://www.stockbloghub.com/2010/02/04/agn-allergan-beats-the-street-outlook-disappoints/26999</link>
		<comments>http://www.stockbloghub.com/2010/02/04/agn-allergan-beats-the-street-outlook-disappoints/26999#comments</comments>
		<pubDate>Thu, 04 Feb 2010 21:31:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26999</guid>
		<description><![CDATA[Allergan, Inc. (AGN) reported fourth quarter earnings of 78 cents per share, a cent above the Zacks Consensus Estimate. While earnings increased 2.6% from the year-ago quarter, revenues increased 15.9% to $1,224.3 million. Allergan also declared a fourth quarter dividend of 5 cents per share. Earnings for the full year came in at $2.78 per share, a cent above the Zacks Consensus Estimate and 8.2% above the year-ago period. Full year revenues increased 2.3% to $4,503.6 million. Segment Performance Specialty pharmaceuticals sales increased 17.7% to $995 million in the fourth quarter with full year sales increasing 5.2% to $3,683.8 million. Eye care pharmaceutical sales increased 21.2% during the fourth quarter. Strong performance of the Alphagan and Combigan franchise and products like Lumigan and Restasis helped drive eye care sales. New ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/04/agn-allergan-beats-the-street-outlook-disappoints/26999/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Beats Estimates &#8211; Raises Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/01/agn-allergan-beats-estimates-raises-outlook/19274</link>
		<comments>http://www.stockbloghub.com/2009/11/01/agn-allergan-beats-estimates-raises-outlook/19274#comments</comments>
		<pubDate>Sun, 01 Nov 2009 21:28:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19274</guid>
		<description><![CDATA[Allergan, Inc. (AGN) reported third quarter earnings of 70 cents per share, a cent above the Zacks Consensus Estimate and 7.7% above the year-ago earnings of 65 cents. We were pleased to see total revenues increase 3.9% to $1,141.3 million in the reported quarter. Specialty pharmaceuticals sales increased 7.8% to $940.6 million. Eye care pharmaceutical sales increased 4.8%. The strong performance of products like Lumigan and Restasis was offset by weakness in the Alphagan and Combigan franchise. Importantly, we were encouraged to see a recovery in Botox sales, which increased 3% from the year-ago period to $327.8 million. Botox sales had been declining during the past few quarters mainly due to weak consumer spending and concerns regarding its safety record. The recovery in Botox sales resulted in Allergan raising its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/agn-allergan-beats-estimates-raises-outlook/19274/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AGN) Allergan Receives FDA Warning</title>
		<link>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287</link>
		<comments>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:23:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Alcon Incorporated]]></category>
		<category><![CDATA[Allergan Incorporated]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13287</guid>
		<description><![CDATA[On Aug. 21, Allergan, Inc. (AGN) received a warning letter from the U.S. Food and Drug Administration’s (FDA) Division of Drug Marketing, Advertising and Communications (DDMAC) regarding a misleading advertisement used by the company for its acne treatment Aczone Gel, 5%. Aczone is a topical gel formulation, which is approved in the U.S. and Canada for the treatment of acne vulgaris in patients 12 years and older. Allergan acquired the product in July 2008 from QLT Inc. for $150 million in order to bolster its skin care franchise. In the warning letter, the FDA stated that the claims made by the company in the advertisement are a misrepresentation of the clinical results. According to the agency, the benefits of Aczone have been overstated. In the advertisement, Allergan claims that Aczone ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/agn-allergan-receives-fda-warning/13287/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

